| Rheumatoid Arthritis
Olumiant vs Rasuvo
Side-by-side clinical, coverage, and cost comparison for rheumatoid arthritis.Deep comparison between: Olumiant vs Rasuvo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRasuvo has a higher rate of injection site reactions vs Olumiant based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rasuvo but not Olumiant, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Olumiant
Rasuvo
At A Glance
Oral
Once daily
JAK inhibitor
SC injection
Once weekly
Folate analog metabolic inhibitor
Indications
- Rheumatoid Arthritis
- COVID-19 Virus Disease
- Alopecia Areata
- Rheumatoid Arthritis
- Juvenile polyarthritis
- Psoriasis
Dosing
Rheumatoid Arthritis 2 mg once daily orally, with or without food; may be used as monotherapy or in combination with methotrexate or other non-biologic DMARDs.
COVID-19 Virus Disease 4 mg once daily orally, with or without food, for 14 days or until hospital discharge, whichever occurs first.
Alopecia Areata 2 mg once daily orally; increase to 4 mg once daily if response is not adequate; reduce back to 2 mg once daily when adequate response is achieved.
Rheumatoid Arthritis 7.5 mg SC once weekly as starting dose; adjust gradually to achieve optimal response; doses greater than 20 mg/wk associated with increased serious toxicity; available doses 7.5-30 mg in 2.5 mg increments.
Juvenile polyarthritis 10 mg/m2 SC once weekly as starting dose; adjust gradually to achieve optimal response.
Psoriasis 10-25 mg SC once weekly as starting dose; adjust gradually; do not ordinarily exceed 30 mg/week; reduce to lowest effective dose and longest possible rest period once optimal response achieved.
Contraindications
—
- Pregnancy
- Alcoholism, alcoholic liver disease, or other chronic liver disease
- Overt or laboratory evidence of immunodeficiency syndromes
- Preexisting blood dyscrasias such as bone marrow hypoplasia, leukopenia, thrombocytopenia, or significant anemia
- Known hypersensitivity to methotrexate
Adverse Reactions
Most common (>=1%) Upper respiratory tract infections, nausea, herpes simplex, herpes zoster, acne, hyperlipidemia, urinary tract infections, headache, fatigue, folliculitis, lower respiratory tract infections, genital Candida infections, anemia, neutropenia, liver enzyme elevations, blood creatine phosphokinase increased, thrombocytosis, deep vein thrombosis, pulmonary embolism
Serious Serious infections, mortality, malignancy and lymphoproliferative disorders, major adverse cardiovascular events, thrombosis, hypersensitivity, gastrointestinal perforations, laboratory abnormalities
Postmarketing Drug hypersensitivity including rash, urticaria, and angioedema
Most common (>=10%) Elevated liver function tests, nausea, vomiting
Serious Ulcerative stomatitis, leukopenia, hepatotoxicity, bone marrow suppression, interstitial pneumonitis, opportunistic infections, embryo-fetal toxicity, malignant lymphomas
Pharmacology
Baricitinib is a JAK inhibitor that selectively inhibits JAK1, JAK2, and TYK2, preventing phosphorylation and activation of STATs and thereby modulating cytokine signaling pathways involved in hematopoiesis and immune cell function.
Methotrexate is a folate analog metabolic inhibitor that inhibits dihydrofolic acid reductase, interfering with DNA synthesis, repair, and cellular replication; in rheumatoid arthritis the mechanism may involve immune function modulation, and in psoriasis it exploits the differential in epithelial cell proliferation rates.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Olumiant
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (9/12)
Rasuvo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Olumiant
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Rasuvo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Olumiant
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Rasuvo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$25/momo
Olumiant Savings Card - Non-covered benefitCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Rasuvo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OlumiantView full Olumiant profile
RasuvoView full Rasuvo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.